NEW YORK, May 31, 2017 /PRNewswire/ --
On Tuesday, May 30, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Six out of nine sectors ended Tuesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Drug Manufacturers - Other equities this morning: Depomed Inc. (NASDAQ: DEPO), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), United Therapeutics Corp. (NASDAQ: UTHR), and Orexigen Therapeutics Inc. (NASDAQ: OREX). Download the free research reports on these stocks today:
Newark, California headquartered Depomed Inc.'s stock finished Tuesday's session 2.84% lower at $9.91. A total volume of 2.18 million shares was traded, which was above their three months average volume of 1.62 million shares. The Company's shares are trading below their 50-day moving average by 18.85%. Moreover, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have a Relative Strength Index (RSI) of 35.17.
On May 10th, 2017, research firm Piper Jaffray upgraded the Company's stock rating from 'Underweight' to 'Neutral'. See our free and comprehensive research report on DEPO at:
Shares in Morristown, New Jersey headquartered Pernix Therapeutics Holdings Inc. declined 8.48%, ending yesterday's session at $3.67 with a total trading volume of 307,546 shares. The stock has gained 13.98% in the previous three months and 89.18% on an YTD basis. The Company's shares are trading 10.69% below their 200-day moving average. Moreover, shares of Pernix Therapeutics, which focuses on the acquisition, development, and commercialization of prescription drugs primarily for the US market, have an RSI of 35.29. PTX free research report PDF is just a click away at:
On Tuesday, Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock saw a slight drop of 0.14%, to close the day at $118.91. A total volume of 490,542 shares was traded. The Company's shares are trading 5.50% below their 50-day moving average. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 34.57. Sign up for your complimentary report on UTHR at:
Shares in La Jolla, California headquartered Orexigen Therapeutics Inc. ended the day 1.35% lower at $2.93. A total volume of 33,856 shares was traded. The stock has gained 68.39% since the start of this year. The Company's shares are trading below their 200-day moving average by 9.36%. Furthermore, shares of Orexigen Therapeutics, which focuses on the development of pharmaceutical products primarily in the US, Europe, and South Korea, have an RSI of 39.01. Register for free on Stock-Callers.com and download the latest research report on OREX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA